Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Gilead’s Veklury recommended by CHMP for COVID-19 in patients with hepatic impairment

If approved, Veklury would become the first COVID-19 antiviral authorised for use across all stages of liver disease

- PMLiVE

Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

Researchers discover how neurons die in Alzheimer’s disease

The findings open up potential avenues to develop new treatments for the condition

- PMLiVE

ICR researchers develop new test to help identify future cancer treatments

The RKD2 test could make the early stages of drug discovery for cancer more efficient

- PMLiVE

How to create value in your business

By Sandy Royden

Church Pharmacy increases productivity

Video of how Church pharmacy moved from a traditional to an automated  set up and increased accuracy to 99%

Kardex

- PMLiVE

Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition

The proposed transaction would mark a significant boost to the US pharma’s oncology pipeline

EU flag

EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia

Inaqovi is the first oral hypomethylating agent approved for this patient population

- PMLiVE

CSL Seqirus highlights impact of flu vaccines on reducing strain on healthcare resources

Flu vaccines for older adults in France could reduce hospitalisations by up to 30%

- PMLiVE

Harnessing innovation to change the future of chronic diseases in Europe

By Stefan Woxström

- PMLiVE

Moderna’s XBB.1.5-adapted COVID-19 vaccine receives MHRA approval

The vaccine has been updated to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

Almirall receives CHMP recommendation for lebrikizumab in atopic dermatitis

The drug has been recommended as a treatment option for adult and adolescent patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links